Elisa Giovannetti
Elisa Giovannetti
Associate Professor - UHD - Amsterdam UMC (VUmc) & FPS, Pisa
Verified email at
Cited by
Cited by
Guidelines for the use and interpretation of assays for monitoring autophagy
DJ Klionsky, FC Abdalla, H Abeliovich, RT Abraham, A Acevedo-Arozena, ...
Autophagy 8 (4), 445-544, 2012
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
A Leonetti, S Sharma, R Minari, P Perego, E Giovannetti, M Tiseo
British journal of cancer 121 (9), 725-737, 2019
MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity
E Giovannetti, N Funel, GJ Peters, M Del Chiaro, LA Erozenci, E Vasile, ...
Cancer research 70 (11), 4528-4538, 2010
Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine
E Giovannetti, M Del Tacca, V Mey, N Funel, S Nannizzi, S Ricci, ...
Cancer research 66 (7), 3928-3935, 2006
Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer
JH Hwang, J Voortman, E Giovannetti, SM Steinberg, LG Leon, YT Kim, ...
PloS one 5 (5), e10630, 2010
Analysis of drug interactions
IV Bijnsdorp, E Giovannetti, GJ Peters
Cancer Cell Culture: Methods and Protocols, 421-434, 2011
Tyrosine kinase inhibitors: Multi-targeted or single-targeted?
F Broekman, E Giovannetti, GJ Peters
World journal of clinical oncology 2 (2), 80, 2011
Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin–treated advanced non–small cell lung cancer patients
C Tibaldi, E Giovannetti, E Vasile, V Mey, AC Laan, S Nannizzi, ...
Clinical cancer research 14 (6), 1797-1803, 2008
Platinum-induced neurotoxicity and preventive strategies: past, present, and future
A Avan, TJ Postma, C Ceresa, A Avan, G Cavaletti, E Giovannetti, ...
The oncologist 20 (4), 411-432, 2015
Swarm intelligence-enhanced detection of non-small-cell lung cancer using tumor-educated platelets
MG Best, N Sol, S GJG, A Vancura, M Muller, ALN Niemeijer, AV Fejes, ...
Cancer cell 32 (2), 238-252. e9, 2017
Discovery of N-Hydroxyindole-Based Inhibitors of Human Lactate Dehydrogenase Isoform A (LDH-A) as Starvation Agents against Cancer Cells
C Granchi, S Roy, C Giacomelli, M Macchia, T Tuccinardi, A Martinelli, ...
Journal of medicinal chemistry 54 (6), 1599-1612, 2011
Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non–small-cell lung cancer cells
E Giovannetti, V Mey, S Nannizzi, G Pasqualetti, L Marini, M Del Tacca, ...
Molecular pharmacology 68 (1), 110-118, 2005
Drug resistance in pancreatic cancer: Impact of altered energy metabolism
C Grasso, G Jansen, E Giovannetti
Critical reviews in oncology/hematology 114, 139-152, 2017
Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice
E Giovannetti, A Erozenci, J Smit, R Danesi, GJ Peters
Critical reviews in oncology/hematology 81 (2), 103-122, 2012
Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolateá…
E Giovannetti, C Lemos, C Tekle, K Smid, S Nannizzi, JA Rodriguez, ...
Molecular pharmacology 73 (4), 1290-1300, 2008
Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective
J Ciccolini, C Serdjebi, GJ Peters, E Giovannetti
Cancer chemotherapy and pharmacology 78, 1-12, 2016
MicroRNAs cooperatively inhibit a network of tumor suppressor genes to promote pancreatic tumor growth and progression
AE Frampton, L Castellano, T Colombo, E Giovannetti, J Krell, J Jacob, ...
Gastroenterology 146 (1), 268-277. e18, 2014
Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia
M Maftouh, A Avan, R Sciarrillo, C Granchi, LG Leon, R Rani, N Funel, ...
British journal of cancer 110 (1), 172-182, 2014
Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer
A Leonetti, B Wever, G Mazzaschi, YG Assaraf, C Rolfo, F Quaini, M Tiseo, ...
Drug Resistance Updates 46, 100644, 2019
c-Met as a target for personalized therapy
I Garajovß, E Giovannetti, G Biasco, GJ Peters
Translational oncogenomics 7 (Suppl 1), 13, 2015
The system can't perform the operation now. Try again later.
Articles 1–20